Flow Neuroscience AB
Developer of a medically certified at-home neuromodulation treatment system for depression. The organisation designs a portable low-intensity transcranial direct current stimulation (tDCS) headset and a companion mobile application, conducts randomized clinical trials and real-world evidence collection, partners with health systems for clinical deployment, and maintains EU/UK device certification and an FDA Breakthrough Device designation for at-home depression treatment.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Portable tDCS headset with companion mobile application
A medical-grade headset that delivers calibrated low-intensity direct current stimulation and pairs with a mobile application to control sessions, provide behavioural therapy content and record standardized symptom measures.
Portable tDCS headset with companion mobile application
A medical-grade headset that delivers calibrated low-intensity direct current stimulation and pairs with a mobile application to control sessions, provide behavioural therapy content and record standardized symptom measures.
Services
Provision of a medically certified at-home tDCS headset paired with a companion mobile application that guides stimulation sessions, delivers behavioural therapy modules and records symptom measures for remote monitoring.
Institutional partnerships to deploy at-home neuromodulation pathways in clinical services, including pilot implementation, clinician training and outcomes monitoring.
Provision of a medically certified at-home tDCS headset paired with a companion mobile application that guides stimulation sessions, delivers behavioural therapy modules and records symptom measures for remote monitoring.
Institutional partnerships to deploy at-home neuromodulation pathways in clinical services, including pilot implementation, clinician training and outcomes monitoring.
Expertise Areas
- At-home neuromodulation for depression
- Clinical trial design and randomized controlled trials
- Real-world evidence generation and patient-reported outcome analytics
- Mobile health (mHealth) application development and connectivity
Key Technologies
- Transcranial direct current stimulation (tDCS)
- Neuromodulation
- Bluetooth-enabled medical device connectivity
- Mobile health applications (iOS, Android)
News & Updates
Large placebo-controlled RCT reported that 10-week at-home tDCS treatment approximately doubled remission rates compared with sham; 57% remission reported in the treatment group.
Regulatory recognition under the FDA Breakthrough Devices program for an at-home device intended for depression treatment.
Medical device certification and compliance with European and UK medical device regulations for at-home tDCS use.
Deployment in multiple NHS trusts with independently published service evaluations, including reports of reduced suicidal ideation and improvements in depressive symptoms across community and crisis services.
Aggregated real-world data from tens of thousands of users across Europe reporting early symptom improvements (77% reported improvement at 3 weeks in a large self-reported sample; retrospective sleep and anxiety improvement analyses reported in separate studies).
Technology validated across multiple peer-reviewed studies and clinical trials; company cites >20 clinical trials and numerous meta-analyses supporting tDCS efficacy for depression.
Large placebo-controlled RCT reported that 10-week at-home tDCS treatment approximately doubled remission rates compared with sham; 57% remission reported in the treatment group.
Regulatory recognition under the FDA Breakthrough Devices program for an at-home device intended for depression treatment.
Medical device certification and compliance with European and UK medical device regulations for at-home tDCS use.
Deployment in multiple NHS trusts with independently published service evaluations, including reports of reduced suicidal ideation and improvements in depressive symptoms across community and crisis services.
Aggregated real-world data from tens of thousands of users across Europe reporting early symptom improvements (77% reported improvement at 3 weeks in a large self-reported sample; retrospective sleep and anxiety improvement analyses reported in separate studies).
Technology validated across multiple peer-reviewed studies and clinical trials; company cites >20 clinical trials and numerous meta-analyses supporting tDCS efficacy for depression.